Eli Lilly and Co.

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Health reform dings Lilly's earnings

April 19, 2010
J.K. Wall
The Indianapolis-based drugmaker also lowered its forecast for full-year profits because the new health care law grants bigger rebates on prescription drugs to federal health insurance programs.
More

Can Lilly afford to maintain its dividend?Restricted Content

April 17, 2010
J.K. Wall
As shareholders gather April 19 for Eli Lilly and Co.'s annual meeting, more of them than ever will come with an unusual question: Will Lilly be able to keep paying its dividend?
More

Lilly sets date for move from Faris campus downtown

April 12, 2010
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
More

Lilly diabetes drug may have cancer risk, FDA says

April 9, 2010
 IBJ Staff and Bloomberg News
Once-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack up sales of $2 billion annually.
More

Louisiana gets $20M in Lilly drug settlement

April 7, 2010
Associated Press
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for uses that had not been approved by federal regulators.
More

Lilly wins court ban on generic copy of Gemzar

April 1, 2010
Bloomberg News, Associated Press
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.
More

Lilly drug wins U.K. backing as cancer therapy

April 1, 2010
Bloomberg News
Eli Lilly and Co.'s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for patients with the most common form of lung cancer.
More

Lilly to let 115 workers go in new outsourcing deal

March 26, 2010
J.K. Wall
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same location.
More

Lilly eyes more animal-health acquisitions

March 25, 2010
 IBJ Staff and Bloomberg News
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.'s plan to combine their veterinary units.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More

Lilly Endowment's assets drop more than foundation peers

March 24, 2010
Andrea Muirragui Davis
Once the nation’s wealthiest foundation, Indianapolis-based Lilly Endowment now ranks ninth among its grant-making peers. The endowment’s value fell 15 percent last year, to an estimated $4.8 billion.
More

Bill kicks off years of change for local health care players

March 22, 2010
J.K. Wall
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers and more will eventually feel impact.
More

Lilly sues to block generic of Adcirca lung treatment

March 17, 2010
Bloomberg News
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
More

Lilly victim of theft from Connecticut warehouse

March 16, 2010
 IBJ Staff and Associated Press
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
More

Lilly pays $50M-plus for rights to testosterone lotion

March 16, 2010
Bloomberg News
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing assets are transferred, but the deal could be worth millions more.
More

FDA says 'not yet' on Lilly's once-weekly Byetta

March 15, 2010
J.K. Wall
Regulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling, manufacturing processes.
More

Eli Lilly to buy European rights to Pfizer animal products

March 8, 2010
Scott Olson
The acquisition will benefit Elanco, Lilly's animal health division in Greenfield, which has become increasingly important to Lilly as it braces for patent-protection losses.
More

Market surge doesn't lift Lilly EndowmentRestricted Content

March 6, 2010
Kathleen McLaughlin
Lilly Endowment's resistance to diversify its holdings reached a new height last year, as it failed to sell a single share of the underperforming Eli Lilly and Co. stock while the broader market surged.
More

Three Indiana companies among world's most admired

March 5, 2010
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

To attack costs, Lilly accelerates R&D

March 3, 2010
J.K. Wall
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep getting higher for Eli Lilly and Co.'s efforts to develop drugs faster and cheaper.
More

Lilly to shift more employees to Covance

February 26, 2010
J.K. Wall
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
More

Obama health reform plan slaps drugmakers

February 24, 2010
J.K. Wall
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals with generic competitor.
More

Lilly, Merck, Pfizer starting research center

February 23, 2010
Associated Press
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT